What is Angelman syndrome (AS)?

Angelman syndrome (AS) is a rare neurogenetic disorder that is estimated to impact about one in 15,000 people, or approximately 500,000 individuals worldwide. Individuals living with AS may have some or all of these common characteristics:

- Neurodevelopmental delays
- Unable to speak verbally
- Seizure activity
- Difficulty with balance and walking
- Disrupted sleep
- Fine motor challenges
- Behaviors such as frequent laughter, smiling, and excitability

While AS is not degenerative, individuals living with AS are currently unable to live independently and require continuous care throughout their life.

What Causes AS?

AS is caused by a genetic difference affecting the *UBE3A* gene of chromosome 15 that results in the absence of UBE3A protein in the brain.

The UBE3A protein in the brain helps us walk, talk, and perform many other everyday tasks.

(Geno)Types of AS

There are multiple different mechanisms or genetic differences that can result in the absence of UBE3A protein. In AS, we call these different genetic mechanisms "genotypes."

The genotypes of AS are: Deletion, Mutation, Uniparental Disomy (UPD), Imprinting Center Defect (ICD), and Mosaic.

Knowing your loved one's AS genotype is important. While each individual living with AS is unique, individuals with the same genotype may have certain characteristics in common. Each genotype has a different chance to be inherited. Finally, many clinical trials have genotype in their inclusion criteria for enrollment.

Learn more & schedule a 1:1 with our certified genetic counselor!

A Roadmap to a Cure

The drug development process is complex. For every drug that makes it through the stages of drug development to approval, there are about 14,999 that do not.

To achieve a future in which there are multiple approved therapeutics, efforts must be multi-pronged to have as many shots on goal as possible. Because of that, the Foundation for Angelman Syndrome Therapeutics (FAST) has created a strategic roadmap that is divided into four pillars.

The four pillars categorize different ways to increase UBE3A protein in the brain, develop treatments for symptoms, and all of the work necessary to bring transformative therapeutics to individuals living with Angelman syndrome.



Check out the Angelman Syndrome Drug Development Pipeline for more information.

This interactive tool summarizes the current therapeutic approaches and enables you to quickly access the latest research news and clinical trial status.

About FAST

The Foundation for Angelman Syndrome Therapeutics (FAST) is the leading patient advocacy organization working to cure Angelman syndrome. As the largest non-governmental funder of Angelman syndrome research in the world, our goal is to drive forward transformative research and development programs as quickly as possible for those living with Angelman syndrome – regardless of age or genotype.

Join the Cure Angelman Network!

The Cure Angelman Network (CAN) is a group determined to support FAST's mission. It is a community of parents, family, friends, medical teams, and others committed to supporting a loved one living with Angelman syndrome and each other.

We encourage you to explore all the network has to offer. We offer opportunities for individuals within the network to learn, participate, advocate, and fundraise – whatever resonates with you – for wherever you are on your journey.

Explore how you can get involved.

Save the Dates

- February 15: International Angelman Day (IAD)
- March: Angelman Syndrome Congressional Advocacy Day in Washington, DC
- November: FAST's Annual Global Science Summit & Gala